US hospitals continue to have high healthcare-associated infection rates according to a joint report by the Leapfrog Group and Castlight Health.
US hospitals continue to have high healthcare-associated infection rates according to a joint report by the Leapfrog Group and Castlight Health.
Using voluntary reports from 1750 hospitals (about 46% of hospitals nationwide), the organizations determined that the majority of intensive care unit facilities are not meeting Leapfrog’s standardized infection ratio (SIR) for central line-associated blood stream infections (CLABSIs) and catheter-associated urinary tract infections (CAUTIs). Combined, these infections cost nearly $10 billion annually.
The SIR is calculated as the facility’s actual infection rate divided by the expected infection rate and is used by the Centers for Disease Control and Prevention and others. The SIR for CLABSI should be 0 and the SIR for CAUTI should be close to 0, yet for both infections only about 25% of hospitals met this standard.
Of the hospitals surveyed, 67% had a CLABSI SIR between 0-1.0, 8% had an SIR above 1.0, and 1% had an SIR above 2.0. Approximately 33% of hospitals had a CAUTI SIR above 1.0. New Hampshire had the best record with 67% of their hospitals having a CLABSI SIR of 0; Maryland and Rhode Island had the worst record with no hospitals reporting CLABSI SIRs of 0.
All hospitals should be able to attain ideal SIRs so long as they adhere to safety guidelines regarding central lines and catheters, and following through with checklists and thorough handwashings.
If more providers reported to Leapfrog then they could “benchmark their own progress in achieving appropriate standards of care, and empower patients to make more informed decisions” by opting for safer facilities.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More